Wuhan Optics Valley Vcanbiopharma

Wuhan Optics Valley Vcanbiopharma is a China-based cell therapy biotech focused on development of mesenchymal stromal cell drugs, particularly cryopreserved human umbilical cord-derived cell injections. The company is a wholly owned subsidiary within the Vcanbio Cell & Gene Engineering group and operates as part of its broader precision medicine and cell therapy strategy. Its lead programs, VUM02 and VUM03, are being developed across multiple inflammatory, fibrotic, immune, and gastrointestinal indications. Publicly disclosed clinical activity includes a recruiting Phase 1 study in idiopathic pulmonary fibrosis and a not-yet-recruiting Phase 1/2 study in steroid-refractory acute graft-versus-host disease. The company has also received U.S. FDA orphan drug designation for a human umbilical cord-derived mesenchymal stem cell injection in idiopathic pulmonary fibrosis.